2025.08.07

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

Full text

2025.07.31

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

Full text

2025.07.27

ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

Full text

2025.07.09

A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint

A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint

Full text

2025.05.31

ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma

ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma

Full text

2025.05.15

Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

Full text

2025.04.18

CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

Full text

2025.03.11

AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development

AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development

Full text

2024.11.18

Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price

Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price

Full text

2024.10.17

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

Full text

2024.10.15

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

Full text

2024.07.23

NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment

NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment

Full text

2024.07.19

Chiglitazar Sodium (Bilessglu®) in Combination with Metformin Approved by NMPA for Type 2 Diabetes

Chiglitazar Sodium (Bilessglu®) in Combination with Metformin Approved by NMPA for Type 2 Diabetes

Full text

2024.06.08

Chipscreen Biosciences' Chidamide tablets designated as a breakthrough therapy for advanced colorectal cancer

Chipscreen Biosciences' Chidamide tablets designated as a breakthrough therapy for advanced colorectal cancer

Full text

2024.04.30

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

Full text